Cargando…

LBODP107 Real World Performance Of The Afirma Xpression Atlas In Bethesda III And IV Thyroid Nodules. A Private Practice Experience

Fine Needle Aspiration (FNA) has modified all methods for diagnosing thyroid cancer; and in conjunction with the Bethesda System and the genomic sequencing classifiers (GSC), clinicians can objectively identify the risk of malignancy of thyroid nodules prior to surgical interventions. To further cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortega, Dayron, Mhaskar, Rahul, Pinero-Pilona, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Tumor Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628258/ http://dx.doi.org/10.1210/jendso/bvac150.1789

Ejemplares similares

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules
por: Hu, Mimi I, et al.
Publicado: (2021)

Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
por: Kim, Na Eun, et al.
Publicado: (2023)

Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules
por: Jin, Xiaobing, et al.
Publicado: (2022)

The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision‐making from a fine‐needle aspiration sample
por: Krane, Jeffrey F., et al.
Publicado: (2020)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

LBODP070 A Rare Neuroendocrine Tumor-Insulinoma
por: Sekhon, Navharsh, et al.
Publicado: (2022)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
por: Zahid, Adnan, et al.
Publicado: (2021)

Managing Bethesda IV thyroid nodules in an iodine-deficient population
por: Badash, Ido, et al.
Publicado: (2023)

LBODP067 Primary Amenorrhea - A Common Referral With An Uncommon Cause
por: Shaikh, Sheeba, et al.
Publicado: (2022)

Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
por: Kuta, Victoria, et al.
Publicado: (2021)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results
por: Chiang, Pi-Ling, et al.
Publicado: (2023)

Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule
por: Li, Fu, et al.
Publicado: (2019)

Malignancy risk in Bethesda class IV thyroid nodules in an iodine deficient region
por: Loderer, Tommaso, et al.
Publicado: (2023)

Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center
por: Godoi Cavalheiro, Beatriz, et al.
Publicado: (2017)

Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules
por: Polavarapu, Preethi, et al.
Publicado: (2021)

Acto que afirma
por: Meléndez, Juana
Publicado: (1976)

Ultrasound-Guided Thermal Ablation of Bethesda IV Thyroid Nodules: A Pilot Study
por: Li, Xinyang, et al.
Publicado: (2021)

Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF(V600E) Mutation
por: Chirayath, Shiga Rappai, et al.
Publicado: (2019)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

The Role of “Critical” Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules
por: Orlando, Giuseppina, et al.
Publicado: (2023)

Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology
por: Yaprak Bayrak, Busra, et al.
Publicado: (2020)

Hashimoto’s Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2022)

An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules
por: Taccogna, Silvia, et al.
Publicado: (2022)

The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules()
por: Alqahtani, Saad M., et al.
Publicado: (2022)

Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy*
por: Lourdes Ng, Jennifer, et al.
Publicado: (2023)

Reproducibility of “The Bethesda System for Reporting Thyroid Cytopathology:” A Retrospective Analysis of 107 Patients
por: Awasthi, Pragati, et al.
Publicado: (2018)

The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis
por: Liu, Ying, et al.
Publicado: (2019)

Analytical Verification Performance of Afirma Genomic Sequencing Classifier in the Diagnosis of Cytologically Indeterminate Thyroid Nodules
por: Hao, Yangyang, et al.
Publicado: (2019)

MON-498 Thyroseq V3 GC for Bethesda III and IV: An Institutional Experience
por: Desai, Dimpi, et al.
Publicado: (2020)

LBODP108 Did You Follow Your Patient After ICI Cessation? A Case of Immune-Related Adverse Event 5 Months Following Completion Of Immunotherapy
por: Kedarisetti, Sreekari, et al.
Publicado: (2022)

LBODP106 Multi-omics Analyses Of MEN1 Missense Mutations Identify Disruption Of Menin-MLL And Menin-JunD Interactions As Critical Requirements For Molecular Pathogenicity
por: Dreijerink, Koen Marie Anton, et al.
Publicado: (2022)

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital
por: Al Dawish, Mohamed, et al.
Publicado: (2020)

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
por: Almahari, Sayed Ali, et al.
Publicado: (2019)

Strain Elastography as a Valuable Diagnosis Tool in Intermediate Cytology (Bethesda III) Thyroid Nodules
por: Stoian, Dana, et al.
Publicado: (2019)

Surgical Outcome and Malignant Risk Factors in Patients With Thyroid Nodule Classified as Bethesda Category III
por: Huang, Jianhao, et al.
Publicado: (2021)

Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making
por: Kloos, Richard T.
Publicado: (2017)

Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study
por: Azizi, Ghobad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rdr7teq0crpunbm197smljqv0b